In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 123-131

  Feng, Mingqian ^a   Zhang, Jingli ^a   Anver, Miriam ^b   Hassan, Raffit ^a   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

H226 NCI H226; Immunotoxin; In vivo bioluminescence imaging; Malignant mesothelioma; Mesothelin; Monoclonal antibody; Mouse xenograft model; Preclinical model

Indexed keywords

FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; IMMUNOTOXIN; IMMUNOTOXIN SS1P; LENTIVIRUS VECTOR; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CARCINOGENICITY; CELL CLONING; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; FUSION GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PERITONEAL CAVITY; PROMOTER REGION; TREATMENT RESPONSE;

EID: 80053209744     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.123     Document Type: Article

References (26)

1. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
2. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.0 Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:24-32.
3. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
4. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40.
5. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
6. Ho M, Hassan R, Zhang J, Wang Q, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
7. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
8. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
9. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571-5.
10. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, Wang XW, Ho M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010;1:141-9.
11. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-16.
12. Ho M, Onda M, Wang Q, Hassan R, Pastan I, Lively M. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15:1751.
13. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17:568-72.
14. Hassan R, Bullock S, Premkumar A, Kreitman RJ., Kindler H, Willingham MC, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
15. Robert J. Kreitman, Raffit Hassan, David J. FitzGerald, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
16. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Donahue CI, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20-30.
17. Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2010; [Epub ahead of print].
18. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6.
19. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
20. Kaneko O, Gong L, Zhang J, Hansen J, Hassan R, Lee B, Ho M. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009;284:3739-49.
21. Yanagihara K, Tsumuraya M, Takigahira M, Mihara K, Kubo T, Ohuchi K, Seyama T. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int J Cancer 2010;126:2835-46.
22. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res 2009;22:283-95.
23. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, Pastan I. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701.
24. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. An-timesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007;13:7166-71.
25. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63.
26. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, FitzGerald D, Ho M. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 2011; 6:e14640.